Navidea Biopharmaceuticals, Inc.

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/bb/aa/17/bbaa1773-ecf8-3f1f-498d-ade794a0be21/mza_12437820159870680474.jpg/600x600bb.jpg

Stock Day Media

1488 episodes

8 months ago

Stock Day Media is the top source for Penny and Micro-Cap news in America. Our Mission is to provide transparency to publicly traded companies and inform the investors directly. Our reach in the stock market community gives Stock Day the ability to find new potential investors that are seeking unique and lucrative opportunities.

All content for Stock Day Media is the property of Stock Day Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Navidea Biopharmaceuticals, Inc. | Ekinops

Stock Day Media

1 year ago

Navidea Biopharmaceuticals, Inc. | Ekinops

Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said "Results are not indicative of a commercially viable product.”

Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops technology to launch its new SD-WAN offer named SD-WAN Essentials, transforming Enterprise connectivity into a stepping stone to the Cloud.

For more information, please visit StockDayMedia.com